Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers

NCT04220073 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005

Interventions

BIOLOGICAL: JS005 (recombinant humanized monoclonal antibody against IL-17A)
DRUG: placebo

Sponsor

Shanghai Junshi Bioscience Co., Ltd.